Most biologics fail not because they lack potency, but because the immune system disagrees. Undetected immunogenic responses Anti-Drug Antibodies (ADA) can derail clinical trials and cost pharma billions. Today, ADA is only visible during late-stage trials. ALP AI fixes this. We combine tonsil-derived immune organoids and generative AI to predict and prevent ADA risk at early R&D stages, saving years and reducing failure.Founded by scientists and engineers from Caltech, ETH, Stanford, and MIT, ALP AI offers the first scalable platform for true human immune response validation. With a $300B+ biologics market growing rapidly, we are building the standard for immunogenicity intelligence.
Total raised: $2.23M
Investors 1
| Date | Name | Website |
| 10.12.2025 | Venture Ki... | venturekic... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.04.2026 | Pre-Seed | $2.23M | - |
Mentions in press and media 3
| Date | Title | Description |
| 30.04.2026 | ALP Bio raises USD 2.2M pre-seed to address immunogenicity risk in antibody development | ALP Bio raised USD 2.2 million in a pre-seed round led by 42CAP, with participation from Venture Kick and a group of strategic angel investors. Immunogenicity, including anti-drug antibody (ADA) responses, remains one of the key challenges ... |
| 30.04.2026 | ALP Bio AG raises CHF 1.75 million pre-seed to de-risk antibody development | Immunogenicity, including anti-drug antibody (ADA) responses, remains one of the most difficult risks in biologics development. These immune responses can reduce therapeutic efficacy, create safety concerns, and force teams to abandon or r... |
| 29.09.2025 | Bluelion welcomes a new batch of pre-seed startups | The 10-week Bluelion Accelerator program for early-stage startups provides selected participants with the platform to advance their business ideas through workshops on fundamental topics around building a thriving business and fundraising ... |